{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T18:45:23Z","timestamp":1746816323018,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatitis B Virus (HBV) is a hepadnavirus that is the principal pathogen underlying viral liver disease in human populations. In this study, we describe the isolation and characterization of a fully human monoclonal antibody for HBV. This HuMab was isolated by a combinatorial screen of the memory B-cell repertoire from an acute\/recovered HBV-infected patient. Lead candidate selection was based upon strong binding and neutralizing activity for live HBV. We provide a detailed biochemical\/biophysical, and subclass characterization of its specificity and affinity against all of the principal HBV genotypes combined with a functional analysis of its in vitro activity. We also demonstrate its potential as a prophylaxis\/therapy in vivo using human liver chimeric mouse models for HBV infection. These data have important implications for our understanding of natural human immunity to HBV and suggest that this potentially represents a new antibody-based anti-viral candidate for prophylaxis and\/or therapy for HBV infection.<\/jats:p>","DOI":"10.1038\/s41541-022-00516-7","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T07:03:31Z","timestamp":1666335811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Defining the specificity and function of a human neutralizing antibody for Hepatitis B virus"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6112-6286","authenticated-orcid":false,"given":"Saket","family":"Jhajharia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fritz","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng Boon","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6640-1144","authenticated-orcid":false,"given":"Kiren","family":"Purushotorman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhuvaneshwari D\/O","family":"Shunmuganathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5730-7095","authenticated-orcid":false,"given":"Conrad En Zuo","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-J\u00fcrgen","family":"Netter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seng Gee","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1139-8996","authenticated-orcid":false,"given":"Paul A.","family":"MacAry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"516_CR1","unstructured":"WHO. Technical Report: Interim Guidance for Country Validation of Viral Hepatitis Elimination (WHO, 2021)."},{"key":"516_CR2","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","volume":"384","author":"C Tr\u00e9po","year":"2014","unstructured":"Tr\u00e9po, C., Chan, H. L. Y. & Lok, A. Hepatitis B virus infection. Lancet 384, 2053\u20132063 (2014).","journal-title":"Lancet"},{"key":"516_CR3","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/hep.29323","volume":"66","author":"AS Lok","year":"2017","unstructured":"Lok, A. S., Zoulim, F., Dusheiko, G. & Ghany, M. G. Hepatitis B cure: from discovery to regulatory approval. Hepatology 66, 1296\u20131313 (2017).","journal-title":"Hepatology"},{"key":"516_CR4","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4049\/jimmunol.1400118","volume":"193","author":"A Palanichamy","year":"2014","unstructured":"Palanichamy, A. et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J. Immunol. 193, 580\u2013586 (2014).","journal-title":"J. Immunol."},{"key":"516_CR5","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.4254\/wjh.v7.i21.2344","volume":"7","author":"Y Tsutsumi","year":"2015","unstructured":"Tsutsumi, Y. et al. Hepatitis B virus reactivation with a rituximab-containing regimen. World J. Hepatol. 7, 2344\u20132351 (2015).","journal-title":"World J. Hepatol."},{"key":"516_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s40880-015-0015-9","volume":"34","author":"KL Chen","year":"2015","unstructured":"Chen, K. L. et al. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival. Chin. J. Cancer 34, 225\u2013234 (2015).","journal-title":"Chin. J. Cancer"},{"key":"516_CR7","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1053\/j.gastro.2012.02.011","volume":"142","author":"G Crespo","year":"2012","unstructured":"Crespo, G., Marino, Z., Navasa, M. & Forns, X. Viral hepatitis in liver transplantation. Gastroenterology 142, 1373\u20131383 e1371 (2012).","journal-title":"Gastroenterology"},{"key":"516_CR8","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.vaccine.2013.01.025","volume":"31","author":"L Both","year":"2013","unstructured":"Both, L. et al. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine 31, 1553\u20131559 (2013).","journal-title":"Vaccine"},{"key":"516_CR9","doi-asserted-by":"crossref","unstructured":"Li, D. et al. A potent human neutralizing antibody Fc-dependently reduces established HBV infections. Elife 6, e26738 (2017).","DOI":"10.7554\/eLife.26738"},{"key":"516_CR10","doi-asserted-by":"publisher","first-page":"9049","DOI":"10.1128\/JVI.01161-14","volume":"88","author":"R Julithe","year":"2014","unstructured":"Julithe, R., Abou-Jaoude, G. & Sureau, C. Modification of the hepatitis B virus envelope protein glycosylation pattern interferes with secretion of viral particles, infectivity, and susceptibility to neutralizing antibodies. J. Virol. 88, 9049\u20139059 (2014).","journal-title":"J. Virol."},{"key":"516_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jcv.2012.04.027","volume":"57","author":"SM Alavian","year":"2013","unstructured":"Alavian, S. M., Carman, W. F. & Jazayeri, S. M. HBsAg variants: diagnostic-escape and diagnostic dilemma. J. Clin. Virol. 57, 201\u2013208 (2013).","journal-title":"J. Clin. Virol."},{"key":"516_CR12","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1111\/liv.14207","volume":"39","author":"R Walsh","year":"2019","unstructured":"Walsh, R. et al. Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: a biomarker for functional cure. Liver Int. 39, 2066\u20132076 (2019).","journal-title":"Liver Int."},{"key":"516_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.virusres.2015.10.024","volume":"211","author":"I Kucinskaite-Kodze","year":"2016","unstructured":"Kucinskaite-Kodze, I. et al. New broadly reactive neutralizing antibodies against hepatitis B virus surface antigen. Virus Res. 211, 209\u2013221 (2016).","journal-title":"Virus Res."},{"key":"516_CR14","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1136\/gutjnl-2014-308964","volume":"65","author":"TY Zhang","year":"2016","unstructured":"Zhang, T. Y. et al. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut 65, 658\u2013671 (2016).","journal-title":"Gut"},{"key":"516_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1089\/153685902761022742","volume":"21","author":"SH Kim","year":"2002","unstructured":"Kim, S. H. & Park, S. Y. Selection and characterization of human antibodies against hepatitis B virus surface antigen (HBsAg) by phage-display. Hybrid. Hybridomics 21, 385\u2013392 (2002).","journal-title":"Hybrid. Hybridomics"},{"key":"516_CR16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1080\/19420862.2015.1134409","volume":"8","author":"W Wang","year":"2016","unstructured":"Wang, W. et al. A human monoclonal antibody against small envelope protein of hepatitis B virus with potent neutralization effect. MAbs 8, 468\u2013477 (2016).","journal-title":"MAbs"},{"key":"516_CR17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1046\/j.1365-2567.1998.00426.x","volume":"93","author":"R Eren","year":"1998","unstructured":"Eren, R. et al. Human monoclonal antibodies specific to hepatitis B virus generated in a human\/mouse radiation chimera: the Trimera system. Immunology 93, 154\u2013161 (1998).","journal-title":"Immunology"},{"key":"516_CR18","doi-asserted-by":"publisher","first-page":"e0125704","DOI":"10.1371\/journal.pone.0125704","volume":"10","author":"A Cerino","year":"2015","unstructured":"Cerino, A., Bremer, C. M., Glebe, D. & Mondelli, M. U. A human monoclonal antibody against hepatitis B surface antigen with potent neutralizing activity. PLoS ONE 10, e0125704 (2015).","journal-title":"PLoS ONE"},{"key":"516_CR19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/jmv.2146","volume":"66","author":"RA Heijtink","year":"2002","unstructured":"Heijtink, R. A. et al. Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant-DNA hepatitis B vaccine. J. Med Virol. 66, 304\u2013311 (2002).","journal-title":"J. Med Virol."},{"key":"516_CR20","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.4014\/jmb.1703.03066","volume":"27","author":"J Wi","year":"2017","unstructured":"Wi, J., Jeong, M. S. & Hong, H. J. Construction and characterization of an anti-hepatitis B virus preS1 humanized antibody that binds to the essential receptor binding site. J. Microbiol. Biotechnol. 27, 1336\u20131344 (2017).","journal-title":"J. Microbiol. Biotechnol."},{"key":"516_CR21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.antiviral.2008.03.006","volume":"79","author":"SH Kim","year":"2008","unstructured":"Kim, S. H. et al. Neutralization of hepatitis B virus (HBV) by human monoclonal antibody against HBV surface antigen (HBsAg) in chimpanzees. Antivir. Res. 79, 188\u2013191 (2008).","journal-title":"Antivir. Res."},{"key":"516_CR22","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/hep.23778","volume":"52","author":"AU Neumann","year":"2010","unstructured":"Neumann, A. U. et al. Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells. Hepatology 52, 875\u2013885 (2010).","journal-title":"Hepatology"},{"key":"516_CR23","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.3748\/wjg.v27.i21.2727","volume":"27","author":"EP Tsounis","year":"2021","unstructured":"Tsounis, E. P., Tourkochristou, E., Mouzaki, A. & Triantos, C. Toward a new era of hepatitis B virus therapeutics: the pursuit of a functional cure. World J. Gastroenterol. 27, 2727\u20132757 (2021).","journal-title":"World J. Gastroenterol."},{"key":"516_CR24","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nbt1326","volume":"25","author":"H Azuma","year":"2007","unstructured":"Azuma, H. et al. Robust expansion of human hepatocytes in Fah-\/-\/Rag2-\/-\/Il2rg-\/- mice. Nat. Biotechnol. 25, 903\u2013910 (2007).","journal-title":"Nat. Biotechnol."},{"key":"516_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1089\/vim.2006.19.277","volume":"19","author":"TH Tsai","year":"2006","unstructured":"Tsai, T. H. et al. Study of IgG subclass profiles of anti-HBs in populations with different HBV infection status. Viral Immunol. 19, 277\u2013284 (2006).","journal-title":"Viral Immunol."},{"key":"516_CR26","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1086\/315515","volume":"181","author":"H Gregorek","year":"2000","unstructured":"Gregorek, H. et al. IgG subclass distribution of hepatitis B surface antigen antibodies induced in children with chronic hepatitis B infection after interferon-alpha therapy. J. Infect. Dis. 181, 2059\u20132062 (2000).","journal-title":"J. Infect. Dis."},{"key":"516_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.chom.2016.05.013","volume":"20","author":"S Seitz","year":"2016","unstructured":"Seitz, S. et al. A slow maturation process renders hepatitis B virus infectious. Cell Host Microbe 20, 25\u201335 (2016).","journal-title":"Cell Host Microbe"},{"key":"516_CR28","doi-asserted-by":"publisher","first-page":"11312","DOI":"10.1128\/JVI.01123-15","volume":"89","author":"M Hyakumura","year":"2015","unstructured":"Hyakumura, M. et al. Modification of asparagine-linked glycan density for the design of hepatitis B virus virus-like particles with enhanced immunogenicity. J. Virol. 89, 11312\u201311322 (2015).","journal-title":"J. Virol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00516-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00516-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00516-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T07:12:23Z","timestamp":1666336343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00516-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["516"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00516-7","relation":{},"ISSN":["2059-0105"],"issn-type":[{"type":"electronic","value":"2059-0105"}],"subject":[],"published":{"date-parts":[[2022,10,21]]},"assertion":[{"value":"23 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The antibody described in the paper (mAb006-11) is part of a patent filing, Singapore patent application number 10202107784Y.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"121"}}